Karyopharm Therapeutics Inc. (KPTI) stock
KPTINasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPTIQ
$0.04−0.01 (-20.00%)
Close on Nov 9, 2026Market cap $1.16KP/E –Yield –
Karyopharm Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Karyopharm Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$82.35M. For fiscal 2025 it was -$90.71M. The highest annual figure on record is -$10.31M in fiscal 2011.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$90.71M | – |
| FY2024 | Dec 31, 2024 | -$119.44M | – |
| FY2023 | Dec 31, 2023 | -$129.54M | – |
| FY2022 | Dec 31, 2022 | -$142.20M | – |
| FY2021 | Dec 31, 2021 | -$98.27M | – |
| FY2020 | Dec 31, 2020 | -$171.85M | – |
| FY2019 | Dec 31, 2019 | -$189.28M | – |
| FY2018 | Dec 31, 2018 | -$179.88M | – |
| FY2017 | Dec 31, 2017 | -$130.54M | – |
| FY2016 | Dec 31, 2016 | -$110.73M | – |
| FY2015 | Dec 31, 2015 | -$119.08M | – |
| FY2014 | Dec 31, 2014 | -$75.85M | – |
| FY2013 | Dec 31, 2013 | -$33.95M | – |
| FY2012 | Dec 31, 2012 | -$15.89M | – |
| FY2011 | Dec 31, 2011 | -$10.31M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$22.53M | – |
| Q1 FY2026 | Mar 31, 2026 | -$26.76M | – |
| Q4 FY2025 | Dec 31, 2025 | -$17.84M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.22M | – |
| Q2 FY2025 | Jun 30, 2025 | -$24.39M | – |
| Q1 FY2025 | Mar 31, 2025 | -$33.26M | – |
| Q4 FY2024 | Dec 31, 2024 | -$31.28M | – |
| Q3 FY2024 | Sep 30, 2024 | -$26.28M | – |
| Q2 FY2024 | Jun 30, 2024 | -$28.12M | – |
| Q1 FY2024 | Mar 31, 2024 | -$33.76M | – |
| Q4 FY2023 | Dec 31, 2023 | -$37.81M | – |
| Q3 FY2023 | Sep 30, 2023 | -$31.26M | – |
| Q2 FY2023 | Jun 30, 2023 | -$29.57M | – |
| Q1 FY2023 | Mar 31, 2023 | -$30.90M | – |
| Q4 FY2022 | Dec 31, 2022 | -$33.87M | -172.1% |
| Q3 FY2022 | Sep 30, 2022 | -$30.84M | – |
| Q2 FY2022 | Jun 30, 2022 | -$42.91M | – |
| Q1 FY2022 | Mar 31, 2022 | -$34.59M | – |
| Q4 FY2021 | Dec 31, 2021 | $46.96M | – |
| Q3 FY2021 | Sep 30, 2021 | -$43.81M | – |
| Q2 FY2021 | Jun 30, 2021 | -$49.05M | – |
| Q1 FY2021 | Mar 31, 2021 | -$52.37M | – |
| Q4 FY2020 | Dec 31, 2020 | -$37.07M | – |
| Q3 FY2020 | Sep 30, 2020 | -$47.11M | – |
| Q2 FY2020 | Jun 30, 2020 | -$40.32M | – |
| Q1 FY2020 | Mar 31, 2020 | -$47.36M | – |
| Q4 FY2019 | Dec 31, 2019 | -$43.27M | – |
| Q3 FY2019 | Sep 30, 2019 | -$39.40M | – |
| Q2 FY2019 | Jun 30, 2019 | -$41.69M | – |
| Q1 FY2019 | Mar 31, 2019 | -$64.92M | – |
| Q4 FY2018 | Dec 31, 2018 | -$57.46M | – |
| Q3 FY2018 | Sep 30, 2018 | -$49.15M | – |
| Q2 FY2018 | Jun 30, 2018 | -$34.33M | – |
| Q1 FY2018 | Mar 31, 2018 | -$38.94M | – |
| Q4 FY2017 | Dec 31, 2017 | -$39.45M | – |
| Q3 FY2017 | Sep 30, 2017 | -$31.06M | – |
| Q2 FY2017 | Jun 30, 2017 | -$29.75M | – |
| Q1 FY2017 | Mar 31, 2017 | -$30.28M | – |
| Q4 FY2016 | Dec 31, 2016 | -$27.17M | – |
| Q3 FY2016 | Sep 30, 2016 | -$25.74M | – |
See a number that looks wrong?